Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (NYSE: ZTS) is described as the world’s leading animal health company, and the ZTS news feed on Stock Titan brings together company announcements, regulatory updates and product developments that shape its story. Zoetis focuses on medicines, vaccines, diagnostics and technologies for animals, serving veterinarians, pet owners and livestock producers in over 100 countries.
News items for Zoetis often highlight its research and development activities and regulatory milestones. Recent releases include Health Canada approval for Portela (relfovetmab injection) to alleviate pain associated with osteoarthritis in cats and European Commission marketing authorization for Lenivia (izenivetmab) to reduce osteoarthritis pain in dogs. These updates illustrate Zoetis’ emphasis on monoclonal antibody therapies and long-acting pain management solutions for companion animals.
Investors can also follow financial and capital markets news, such as announcements of convertible senior notes offerings, senior notes issuances and the use of proceeds for share repurchases and capped call transactions. The company regularly reports dividends declared by its board of directors and provides quarterly and annual financial results through press releases and Form 8-K filings.
Zoetis participates in major healthcare conferences and hosts webcasts, including innovation-focused events that discuss its pipeline across chronic kidney disease, oncology, cardiology, osteoarthritis pain and dermatology. These events, along with earnings calls and conference presentations, are frequently covered in the news stream.
By monitoring the ZTS news page, readers can review product approvals, R&D updates, capital allocation decisions, credit facility arrangements and governance developments reported by Zoetis. This page can be revisited to see how new therapies, financial actions and strategic communications are disclosed over time.
Zoetis Inc (NYSE:ZTS) has announced a fourth-quarter dividend of $0.20 per share, set to be paid on December 1, 2020. The dividend will benefit stockholders of record as of October 21, 2020. With a strong market position in animal health, Zoetis generated $6.3 billion in revenue in 2019, underscoring its operational strength across 100 countries. This dividend declaration reflects the company's commitment to returning value to shareholders while maintaining a solid financial framework.
Zoetis Inc (NYSE:ZTS) is set to hold a webcast and conference call on November 5, 2020, at 8:30 a.m. ET. CEO Kristin Peck and CFO Glenn David will discuss Q3 2020 financial results and answer questions from analysts. Investors can access the live presentation on Zoetis' investor website, with a replay available later on the same day. Zoetis continues to be a leading company in animal health, generating $6.3 billion in revenue in 2019 and serving customers across more than 100 countries.
On July 7, 2020, Trianni and Zoetis announced a collaboration to develop transgenic monoclonal antibody platforms aimed at discovering new veterinary treatments. This partnership is expected to leverage Trianni's advanced technology, which focuses on generating fully-human monoclonal antibodies, thus enhancing Zoetis' product development initiatives. The companies believe this collaboration will accelerate the creation of innovative therapeutics for animal health. No financial details regarding the collaboration have been disclosed.